H.C. Wainwright downgraded G1 Therapeutics to Neutral from Buy with a price target of $7.15, up from $3, after the company entered into a definitive merger agreement for Pharmacosmos to acquire all outstanding shares of G1 Therapeutics common stock at a price of $7.15 per share. The firm cites the pending takeover for the downgrade.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GTHX:
- G1 Therapeutics Acquisition and Executive Compensation Revamp
- Pharmacosmos Group to Acquire G1 Therapeutics
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
- G1 Therapeutics added to Russell 2000, 3000 Indexes